{"id":"NCT02118896","sponsor":"Astellas Pharma Europe Ltd.","briefTitle":"Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","officialTitle":"A Long-term Follow up Study to Evaluate the Safety and Efficacy in Transplant Recipients Treated With Modified Release Tacrolimus, FK506E (MR4), Based Immunosuppression Regimen","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-02-24","primaryCompletion":"2009-10-07","completion":"2009-10-07","firstPosted":"2014-04-21","resultsPosted":"2016-03-15","lastUpdate":"2024-11-22"},"enrollment":850,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Heart Transplantation","Liver Transplantation","Kidney Transplantation"],"interventions":[{"type":"DRUG","name":"FK506E","otherNames":["Astagraf XL","Advagraf","Graceptor","MR4","Prograf XL"]}],"arms":[{"label":"1: FK506E (MR4)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to offer patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) the possibility to continue FK506E (MR4) until commercial availability of the drug and to record long term efficacy and safety data.","primaryOutcome":{"measure":"Participant Survival","timeFrame":"Up to 5.5 years (66 months (phase II) and 24 months (phase III)).","effectByArm":[{"arm":"FG-506-11-01","deltaMin":0.9092,"sd":null},{"arm":"FG-506E-12-01","deltaMin":1,"sd":null},{"arm":"FG-506E-12-02","deltaMin":0.9356,"sd":null},{"arm":"FG-506-15-02","deltaMin":0.9031,"sd":null},{"arm":"FG-506E-11-03","deltaMin":0.9536,"sd":null},{"arm":"FG-506E-12-03","deltaMin":0.9933,"sd":null},{"arm":"PMR-EC-1105","deltaMin":1,"sd":null},{"arm":"PMR-EC-1205","deltaMin":1,"sd":null},{"arm":"PMR-EC-1209","deltaMin":1,"sd":null},{"arm":"PMR-EC-1210","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":105,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Germany","Hungary","Ireland","Italy","Mexico","Netherlands","New Zealand","Poland","South Africa","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://astellasclinicalstudyresults.com/study.aspx?ID=304"]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":47},"commonTop":["Hypertension","Diarrhoea","Anaemia","Urinary tract infection bacterial","Oedema peripheral"]}}